Eloralintide

What Is Eloralintide?

Eloralintide is a laboratory-made peptide, a short chain of building blocks called amino acids. It was developed by Eli Lilly and was first known by its research code, LY3841136.

It is given as an injection under the skin once a week in clinical trials. Lilly calls it a selective amylin receptor agonist. In plain language, a receptor is a structure on a cell that receives a specific message, and an agonist is a substance that switches that receptor on. Eloralintide is built to switch on the receptors that normally respond to amylin.

Is “Elora” the Same as Eloralintide?

“Elora” is an informal nickname used online and by sellers. It is not an official medical name. Eloralintide is the name used in clinical research and by its developer.

A product labeled “Elora” is not automatically the same substance Lilly tests in its trials. The name on a vial does not confirm what is inside it.

How Does Eloralintide Work?

Amylin is a hormone the pancreas releases together with insulin after you eat. It helps you feel full, slows how quickly food leaves the stomach and helps limit blood-sugar spikes after meals.

Eloralintide is designed to imitate that fullness signal, with effects that last for days instead of minutes. Lilly says it may reduce how many calories people eat, likely by helping them feel satisfied sooner. The company also states that the finer details of how it works are still being studied.

Eloralintide is not a GLP-1 medicine. Semaglutide and tirzepatide act mainly through the GLP-1 hormone pathway. Amylin is a separate fullness signal, which is why researchers are also testing amylin-based medicines alongside GLP-1 treatments.

What Have Human Studies Found?

The main published study is a phase 2 clinical trial published in The Lancet in 2025. It included 263 adults in the United States with obesity, or with overweight plus a weight-related health problem. None had type 2 diabetes.

Participants received weekly injections of eloralintide at several different doses, or a placebo, for 48 weeks. Neither participants nor researchers knew who received which treatment.

• Average weight loss ranged from about 9% at the lowest dose to about 20% at the highest doses.
• People receiving placebo lost an average of 0.4%.
• Higher doses generally produced more weight loss, along with more side effects.

These figures describe people who stayed on their assigned treatment, an approach called the efficacy estimand. The trial was funded by Lilly, involved a few hundred people and lasted less than a year. It shows that eloralintide deserves larger studies, not that it is proven safe and effective for everyone.

Larger Phase 3 Trials

Lilly is now testing eloralintide in a phase 3 program called ENLIGHTEN. As of October 2026, ClinicalTrials.gov lists these studies as recruiting:

• ENLIGHTEN-1: adults with obesity or overweight who do not have type 2 diabetes, with about 1,980 planned participants.
• ENLIGHTEN-2: adults with obesity or overweight and type 2 diabetes, with about 1,035 planned participants.
• ENLIGHTEN-6: adults who still have obesity while already taking a weekly incretin medicine, such as a GLP-1 treatment, with about 900 planned participants.

Results from these trials have not been published yet.

Eloralintide vs Cagrilintide

Both medicines are built around amylin, so they are often compared. They are different molecules from different companies.

We did not find a published trial comparing eloralintide and cagrilintide directly. Their studies enrolled different people and used different designs, so their weight-loss numbers should not be ranked against each other. Learn more about cagrilintide.

Eloralintide Side Effects

In the phase 2 trial, the most common side effects were nausea and tiredness. Both were more common at higher doses.

• Nausea affected up to 64% of people in one higher-dose group, compared with 14% receiving placebo.
• Fatigue affected up to 46% of people in one higher-dose group, compared with 12% receiving placebo.
• Rates at the two lowest doses were close to placebo.

Lilly reported that these effects were less common when the dose was increased gradually. Long-term safety, effects during pregnancy, interactions with other medicines and results in larger and more varied groups of people are still unknown. Safety findings from carefully manufactured trial medicine do not apply to products of unknown quality.

Is Eloralintide FDA Approved?

No. As of October 2026, eloralintide is an investigational medicine. It has not been approved by the FDA or any other regulator for weight loss or any other use.

“Research use only” labels mean a product is sold for laboratory research, not as a medicine for people. The label does not prove that a vial contains authentic eloralintide, matches its listed amount, is sterile or is safe to inject.

The Bottom Line

Eloralintide is an experimental amylin-based medicine that produced meaningful weight loss in a 48-week trial, with nausea and tiredness as common side effects at higher doses. Larger trials are underway, and it is not approved.

When you see “Elora” online, the most useful questions are who was studied, how long the study lasted and what side effects appeared. Those answers say more than a nickname or a single percentage about eloralintide.